Cefuroxime Axetil Tablets

We are offering cefuroxime axetil tablets.
about cefuroxime axetil
cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:
1. pharyngitis/tonsillitis caused by streptococcus pyogenes.
2. acute bacterial otitis media caused by streptococcus pneumoniae, haemophilus influenzae (including beta-lactamase-producing strains), moraxella catarrhalis (including beta-lactamase-producing strains), or streptococcus pyogenes.
3. acute bacterial maxillary sinusitis caused by streptococcus pneumoniae or haemophilus influenzae (non-beta-lactamase-producing strains only).
4. acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by streptococcus pneumoniae, haemophilus influenzae (beta-lactamase negative strains), or haemophilus parainfluenzae (beta-lactamase negative strains).
5. uncomplicated skin and skin-structure infections caused by staphylococcus aureus (including beta-lactamase-producing strains) or streptococcus pyogenes.
6. uncomplicated urinary tract infections caused by escherichia coli or klebsiella pneumoniae.
7. uncomplicated gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase- producing strains of neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase- producing strains of neisseria gonorrhoeae.
8. early lyme disease (erythema migrans) caused by borrelia burgdorferi.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets, usp and other antibacterial drugs, cefuroxime axetil tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.